Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Louisiana: - Louisiana Hematology Oncology Associates LLC — Baton Rouge, Louisiana
- Mary Bird Perkins Cancer Center - Covington — Covington, Louisiana
- Ochsner Hematology Oncology North Shore - Covington (West Region) — Covington, Louisiana
- Louisiana State University Health Science Center — New Orleans, Louisiana
- University Medical Center New Orleans — New Orleans, Louisiana
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a poly…
Sponsor: NRG Oncology
NCT ID: NCT06580314
Sites in Louisiana: - LSU Health Baton Rouge-North Clinic — Baton Rouge, Louisiana
- Our Lady of the Lake Physician Group — Baton Rouge, Louisiana
- Our Lady of The Lake — Baton Rouge, Louisiana
- Our Lady of the Lake Medical Oncology — Baton Rouge, Louisiana
- West Jefferson Medical Center — Marrero, Louisiana
Phase 3 Recruiting Network
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…
Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Sites in Louisiana: - University Medical Center New Orleans — New Orleans, Louisiana
- Children's Hospital New Orleans — New Orleans, Louisiana
- Ochsner Medical Center Jefferson — New Orleans, Louisiana
Phase 3 Recruiting Industry
This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A enrolls participants with p…
Sponsor: Eli Lilly and Company
NCT ID: NCT07213804
Sites in Louisiana: - Ochsner Clinic Foundation — New Orleans, Louisiana
- Trials 365 — Shreveport, Louisiana
Phase 3 Recruiting Network
Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadj…
Sponsor: GOG Foundation
NCT ID: NCT05659381
Sites in Louisiana: - LSU Health New Orleans — New Orleans, Louisiana
- University Medical Center New Orleans — New Orleans, Louisiana
Phase 3 Recruiting Industry
The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
Sponsor: Incyte Corporation
NCT ID: NCT07214779
Sites in Louisiana: - Women'S Cancer Care — Covington, Louisiana
Phase 3 Recruiting Industry
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Sponsor: Verastem, Inc.
NCT ID: NCT06072781
Sites in Louisiana: - Louisiana State University — New Orleans, Louisiana
Phase 3 Recruiting Industry
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer get…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06824467
Sites in Louisiana: - Women's Cancer Care ( Site 0067) — Covington, Louisiana
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard ca…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07318558
Sites in Louisiana: - Women's Cancer Care ( Site 0018) — Covington, Louisiana
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Louisiana: - East Jefferson General Hospital — Metairie, Louisiana
- University Medical Center New Orleans — New Orleans, Louisiana
- Ochsner Medical Center Jefferson — New Orleans, Louisiana
Phase 2 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with fo…
Sponsor: AbbVie
NCT ID: NCT06890338
Sites in Louisiana: - Women'S Cancer Care /ID# 276469 — Covington, Louisiana
- University Medical Center New Orleans /ID# 274755 — New Orleans, Louisiana
- Trials 365 /ID# 274310 — Shreveport, Louisiana
Phase 2 Recruiting Industry
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
Sponsor: Incyte Corporation
NCT ID: NCT07023627
Sites in Louisiana: - Trials365, Llc — Shreveport, Louisiana
Phase 2 Recruiting Industry
Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine …
Sponsor: AbbVie
NCT ID: NCT07059845
Sites in Louisiana: - Our Lady of the Lake Physician Group - Medical Oncology /ID# 277440 — Baton Rouge, Louisiana
Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
Sponsor: Cybrexa Therapeutics
NCT ID: NCT06315491
Sites in Louisiana: - Women's Cancer Care — Covington, Louisiana
Phase 2 Recruiting Industry
Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 80 participants will be enrolled. The study will assess the effi…
Sponsor: MacroGenics
NCT ID: NCT06730347
Sites in Louisiana: - Ochsner MD Anderson Cancer Center — New Orleans, Louisiana
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Louisiana: - LSU Health Baton Rouge-North Clinic — Baton Rouge, Louisiana
- Our Lady of the Lake Physician Group — Baton Rouge, Louisiana
- Our Lady of The Lake — Baton Rouge, Louisiana
- Louisiana Hematology Oncology Associates LLC — Baton Rouge, Louisiana
- Louisiana Hematology Oncology Associates — Baton Rouge, Louisiana
NA Recruiting Academic/Other
This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves…
Sponsor: NRG Oncology
NCT ID: NCT04251052
Sites in Louisiana: - West Jefferson Medical Center — Marrero, Louisiana
- Louisiana State University Health Science Center — New Orleans, Louisiana
- University Medical Center New Orleans — New Orleans, Louisiana
- Willis-Knighton Medical and Cancer Center — Shreveport, Louisiana
Recruiting Industry
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinica…
Sponsor: Guardant Health, Inc.
NCT ID: NCT05059444
Sites in Louisiana: - Tulane Cancer Center — New Orleans, Louisiana
- Christus Highland/ Boniol — Shreveport, Louisiana
Recruiting Academic/Other
The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus…
Sponsor: Mayo Clinic
NCT ID: NCT05051722
Sites in Louisiana: - Ochsner Clinic Foundation — New Orleans, Louisiana